Application

Research CategoryApoptosis & Cancer

Detect MAP1 using this rabbit polyclonal antibody, Anti-LC3B Antibody validated for use in western blotting.

Research Sub CategoryApoptosis - Additional

Western Blotting Analysis: A representative lot from an independent laboratory detected LC3B in shRNA control HeLa cell lysates and demonstrated a loss of signal in TBC1D5 knockdown HeLa cell lysates. HeLa cells were either serum starved, or treated with bafilomycin A1 or serum starved in the presence of bafilomycin A1 (Popovic, D., et al. (2012). Mol Cell Biol. 32(9):1733-1744.).
Immunohistochemistry (Paraffin) Analysis: A 1:500 dilution from a representative lot detected LC3B in human cerebral cortex and rat cerebral cortex tissue sections.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

MAP1LC3B, also known as Autophagy-related protein LC3 B, LC3B, Autophagy-related ubiquitin-like modifier LC3 B, MAP1 light chain 3-like protein 2, MAP1A/MAP1B light chain 3 B, MAP1A/MAP1B LC3 B, Microtubule-associated protein 1 light chain 3 beta, and encoded by the gene MAP1LC3B/MAP1ALC3, is a ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes). MAP1LC3B plays a role in mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. Whereas LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation. MAP1LC3B interacts at microtubules with CABP1 (via EF-hands 1 and 2) but not with calmodulin. MAP1LC3B interacts with FYCO1 (via C-terminus). MAP1LC3B interacts with TP53INP1 and TP53INP2, and MAP1LC3B interacts with TBC1D25. MAP1LC3B directly interacts with SQSTM1; this interaction leads to MAP1LC3B recruitment to inclusion bodies containing polyubiquitinated protein aggregates and to inclusion body degradation by autophagy. MAP1LC3B interacts with ATG4B, MAPK15 and BNIP3 protein as well. MAP1LC3B is localized to the cytoplasm and cytoskeleton membranes, specifically endomembranes and cytoplasmic vesicles in the autophagosome. MAP1LC3B is expressed in most abundantly in heart, brain, skeletal muscle and testis tissues, with very low expression in liver tissues. Interestingly, high expression of MAP1LC3B in triple negative breast cancer (TNBC) is associated with poor outcomes in TNBC patients and is currently being studied as a prognostic evaluation marker for patients with TNBC.

Immunogen

Linear peptide corresponding to human LC3B.

Physical form

Rabbit polyclonal serum with 0.05% sodium azide.

Unpurified

Quality

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:2,000 dilution of this antibody detected LC3B in 10 µg of HeLa cell lysate.

Storage and Stability

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Target description

~15 kDa observed